Latest News

11th April, 2019

OncoImmunity will start collaborating with a US-based neoantigen specific T-cell therapy company

OncoImmunity announced today the signing of a collaboration agreement with a T cell therapy company based in the US . The companies will cooperate to access the predictive capabilities of OncoImmunity's artificial intelligence platform called the Immuneoprofiler™ to identify immunogenic neoantigens for the US partner’s T-cell platform.

The collaboration agreement marks the increasing potential of the Immuneoprofiler™ platform to identify optimal neoantigen targets for personalized cell therapy, in addition to the personalized cancer vaccine market.

Please enable your browser to accept cookies and refresh this page to enjoy the best experience from this website and to dismiss this message.
In order to provide you with the best online experience this website uses cookies. By using our website, you agree to our use of cookies.OK